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Kazunori Ogawa and Kuniaki IyodaAbstract
This report describes 3 year old girl with the unusual presentation of polyarticular juvenile idiopathic arthritis (JIA) with
anti-cyclic citrullinated peptide (anti-CCP) antibodies and a positive rheumatoid factor (RF). She was initially treated
with a nonsteroidal anti-inflammatory drug (NSAID; ibuprofen) followed by methotrexate (MTX, 10 mg/m2/week) and
prednisolone (0.25 mg/kg/day), but these treatments were ineffective. Administration of tocilizumab, a humanized
antihuman interleukin-6 receptor monoclonal antibody, promptly improved her clinical manifestations, and she has
been in complete remission (DAS28 <2.6) without bone erosion and/or destruction. Positivity for both antibodies
(anti-CCP and RF) can forecast the severity of JIA (radiographic bone destruction). In such cases the administration of
biologic remissive therapy may be prudent early in the disease course.
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Juvenile idiopathic arthritis (JIA), previously called
“juvenile chronic arthritis” or “juvenile rheumatoid
arthritis”, is the most common chronic autoimmune
(auto-inflammatory) disease in childhood. The disease
affects roughly 10 to 20 in 100,000 children [1]. The
underlying etiology of JIA is still unknown, and a lack
of reliable biomarkers often delays diagnosis and
makes the predicting of a child’s prognosis difficult.
The IgM rheumatoid factor (RF) has been commonly
used as a marker for the diagnosis of adult rheumatoid
arthritis (RA) patients, but it has only been of value in
diagnostic procedures for the small subset of JIA
patients with polyarticular symptoms, often adolescents
with small joint disease [1].
The anti-cyclic citrullinated peptide (anti-CCP) anti-
bodies have been studied extensively in adult-onset RA
and have proved to be highly specific for this disease* Correspondence: k-yasui@city-hosp.naka.hiroshima.jp
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reproduction in any medium, provided the or(98%) [2]. Recent studies have revealed a possible role
for anti-CCP antibodies in forecasting the severity of
RA, with rapid radiographic progression [3-5]. Anti-
CCP antibodies appear to be a predictive factor as they
are accurate indicators that RA will occur within 3 years
[6]. Meanwhile, for the diagnosis of JIA in childhood,
the specificity of anti-CCP is extremely high (>95%) but
its sensitivity is low, ranging from 2 to 14% [7-9]. Anti-
CCP antibodies are present in the polyarticular, IgM
RF-positive subset of JIA patients but are not valuable
for the diagnosis of JIA in general [7-9]. Previous studies
revealed that JIA patients who are positive for anti-CCP
antibodies had severe clinical arthritis and radiological
bone damage [9,10]. Anti-CCP may also be an independ-
ent predictor of radiological damage and disease progres-
sion [4,10]. Their simultaneous presence (anti-CCP and
IgM-RF) may be an indication for more aggressive im-
munosuppressive treatments such as the use of biological
therapy.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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A Japanese girl, aged 3 years and 5 months, was referred
to us for a 2-month history of bilateral knee, hand, and
finger joint arthralgia with morning stiffness. She was
born as a preterm infant at 28 weeks’ gestation by elective
Caesarian section for fetal distress. Her birth weight was
872 g and she was under mechanical ventilation for 14
days. After that, her development was good and she
remained healthy until 2 months before admission. Phys-
ical examination showed a well-appearing girl 93.2 cm
tall and weighing 12.1 kg. Clinical examination revealed
swelling and pain in bilateral knee joints, wrist joints, foot
joints, hip joints and several metacarpophalangeal and
proximal interphalangeal joints. She was unable to walk
alone. Magnetic resonance imaging with T2 enhancement
showed a synovial fluid collection without joint or bone
destruction (Figure 1). The patient had moderate acute-
phase responses, as indicated by the WBC count
(15,000/μl), platelet count (67.3 × 104/μl), CRP (54 mg/l),Figure 1 a) MRI of the pelvis, lower extremities and hip and knee join
with synovial thickening and/or fluid collection but without bone destructi
demonstrates chronic inflammation with synovial thickening and/or fluid cand erythrocyte sedimentation rate (62 mm/hr). Other
initial laboratory investigations showed increased levels of
immunoglobulins G (22,860 mg/l), M (3,610 mg/l), and A
(2,780 mg/l) as well as matrix metalloprotease-3 (MMP-3;
229.9 ng/ml). There were normal levels of ferritin (61.3
ng/ml), hyaluronic acid (36 ng/ml) and IgD (5 mg/l); liver
function was also normal. Antinuclear antibodies (ANA)
were positive (1:160). Anti-CCP antibody and IgM-RF
were both positive (43.2 U/ml, 39.1 IU/ml respectively).
The cut-off value for anti-CCP is 5.0 U/ml, and that for
IgM-RF is 15.0 IU/ml. She had no iritis. She did not
develop any of the other autoantibodies examined, and
had no family history of rheumatic diseases or auto-
immunity. Once the diagnosis of RF-positive polyarticular
JIA was made, a non-steroidal anti-inflammatory drug
(NSAID; ibuprofen, 30 mg/kg/day) was initially started.
The Disease Activity Score (DAS) 28 is defined as
0.56 × √T28 + 0.28 × √S28 + 0.70 × ln(ESR) + 0.014 ×
general health (GH; patient assessment of disease activityts. Fat SAT T2-weighted image demonstrates chronic inflammation
on. b) MRI of hands and fingers. Fat SAT T2-weighted image
ollection but without bone destruction.
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100=worst); our patient’s score was 6.39 [11].
Her symptoms were not controlled for the 3 weeks of
the initial treatment. In succession, methotrexate (MTX,
10 mg/m2/week) and prednisolone (0.25 mg/kg/day) were
added. During the next 6 weeks, acute-phase reactant
levels did not decrease and DAS28 did not change (5.52)
(Figure 2). Finally, tocilizumab was administered intraven-
ously once every 4 weeks at a dose of 8 mg/kg. During
this treatment period, the patient’s clinical symptoms
began to improve rapidly. The level of acute-phase
reactant returned to normal (CRP<0.1 mg/l), and the
DAS 28 was 1.28 after the third administration of tocili-
zumab. After this dramatic improvement of the disease,
we tapered and then stopped prednisolone treatment.
The symptoms and signs of the disease did not recur for
the next two years. The radiographic outcome was
determined as normal and the serum concentration of
MMP-3 was lower than 12.0 ng/ml. Her growth has
been good. Anti-CCP antibody and IgM-RF titers were
still positive; however, the values were lower (6.3 U/ml,
19.0 IU/ml respectively).
Discussion
This is a report of the youngest child ever reported to
develop both anti-CCP antibody positive and IgM-RF
positive polyarticular JIA. Anti-CCP antibodies are now
considered important markers for the diagnosis of RA
in adults. In JIA, which is a very heterogenous groups of
diseases compared to adult RA, the development of
anti-CCP Abs is variable. High anti-CCP positivity is
supposed to be related to highly RF-positive disease,
and the RF-positive polyarticular type of JIA might be aFigure 2 Clinical course of the patient with anti-CCP antibodies and R
8 mg/kg. Disease activity score (DAS) 28 is defined as 0.56 × √T28 + 0.28 ×
assessment of disease activity using a 100-mm visual analogue scale with 0pediatric equivalent of RA [9]. JIA mimicking adult RA
has been reported in another 3-year old girl [12]. This
child was reported to have severe, progressive, and ero-
sive arthritis of the spine, shoulders, and extremities as
well as pulmonary involvement. The patient had a high
titer of RF, but an anti-CCP antibody was not measured.
So, our patient is the youngest case with both anti-CCP
antibody and IgM-RF to be reported worldwide.
She was born as a preterm infant. Interestingly, it is
hypothesized that the pathogenesis of RA may be
related to early life factors, such as birth weight and
breastfeeding, which contribute to the development and
shaping of the immune system [13]. Recent population-
based case–control studies have explored a perinatal
factor (e.g., breast feeding) in association with RA [14].
Yet our patient was fed cows’ milk.
Gestational age and prematurity may be related to in-
fection susceptibility and to in utero maturation, but did
not appear to be associated with RA incidence in either
cohort [14-16]. Meanwhile, preterm birth was recently
found to be a risk factor for systemic lupus erythematosus
and related autoimmune conditions [17]. The immature
immune system of a preterm neonate may be ill-suited to
long-term alterations to the immune system. In our
opinion, altered lymphocyte homeostasis in the thymus
may lead to the development of autoimmunity.
It is suggested that JIA with both RF and anti-CCP
positive antibodies is a more aggressive and severe
disease that leads to joint damage and disability [10]. To
prevent these poor outcomes, it appears prudent to
formulate aggressive treatment strategies immediately.
For our patient, the administration of tocilizumab was
planned from an early stage. Evaluation of the efficaciesF. Tocilizumab was administered once every 4 weeks at a dose of
√S28 + 0.70 × ln(ESR) + 0.014 x general health (GH; patient
=best, 100=worst).
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six weeks revealed no improvement. We then started
the biologic and could conclude that the tocilizumab
had brought about remission without the development
of joint erosion and/or destruction at the 2-year follow-up.
Serum MMP-3 is useful for assessment of inflammatory
erosive arthritis [18]; here, the value of MMP-3 decreased
with tocilizumab therapy in accordance with the remission
of the disease. Although anti-CCP and IgM-RF were still
positive, the values were lowered.
The importance of these antibodies in the evaluation
of JIA and determination of possible treatment plans to
prevent joint damage and disability was demonstrated.
More studies are needed to resolve the precise roles of
anti-CCP in JIA and to determine whether or not it
works as a valuable marker for the selection of optimal
treatments.
Conclusions
This is a report of the youngest child known to develop
anti-CCP antibody and RF double-positive polyarticular
JIA who was successfully treated by tocilizumab. Early
treatment of children with both RF and anti-CCP
antibodies with a biologic may be optimal.
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